Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: An open-label, dose-escalation, phase 1 trial

The Lancet Oncology

Volumn 17, Issue 5, 2016, Pages 622-631

  Younes, Anas ^a   Berdeja, Jesus G ^b   Patel, Manish R ^b,c   Flinn, Ian ^b   Gerecitano, John F ^a   Neelapu, Sattva S ^d   Kelly, Kevin R ^e   Copeland, Amanda R ^a   Akins, Amy ^b   Clancy, Myles S ^f   Gong, Lucy ^f   Wang, Jing ^f   Ma, Anna ^f   Viner, Jaye L ^f   Oki, Yasuhiro ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c Florida Cancer Specialists   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f CURIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CUDC 907; HISTONE DEACETYLASE INHIBITOR; LOPERAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG; CUDC-907; HISTONE DEACETYLASE; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PYRIMIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ADVERSE DRUG REACTION; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FAILURE TO THRIVE; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HEART TAMPONADE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; INFLUENZA; LARGE CELL LYMPHOMA; LYMPH NODE PAIN; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; UROSEPSIS; VASCULAR ACCESS; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MORPHOLINES; MULTIPLE MYELOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINES;

EID: 84961933254     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00584-7     Document Type: Article

References (30)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 2013, International Agency for Research on Cancer, Lyon, France, (accessed Aug 7, 2015). http://globocan.iarc.fr.
2. West AC, Johnstone RW New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014, 124:30-39.
3. Akinleye A, Avvaru P, Purqan M, Song Y, Liu D Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol 2013, 6:88.
4. Qian C, Lai CJ, Bao R, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 2012, 18:4104-4113.
5. Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM-and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res 2014, 20:4849-4860.
6. Lackner MR, Wilson TR, Settleman J Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 2012, 8:999-1014.
7. Bao R, Wang D, Qu H, et al. Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models. Cancer Res 2012, 72(suppl):3744.
8. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
9. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
10. Beleodaq package insert 2014, Spectrum Pharmaceuticals, Spectrum Pharmaceuticals, Inc, Irvine, CA.
11. Farydak package insert 2015, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
12. Istodax package insert 2014, Celgene Corporation, Celgene Corporation, Summit, NJ.
13. Zolinza package insert 2006, Merck & Co, Inc, Merck & Co, Inc, Whitehouse Station, NJ.
14. Zydelig package insert 2014, Gilead Sciences, Inc, Gilead Sciences, Inc, Foster City, CA.
15. Friedberg JW Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011, 2011:498-505.
16. Mondello P, Younes A Emerging drugs for diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 2015, 15:439-451.
17. Ribrag V, Soria JC, Reyderman L, et al. Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histome methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphoma. Eur J Cancer 2014, 50:197.
18. Palanca-Wessels MC, Salles GA, Czuczman MS, et al. Final results of a phase 1 study of the anti-CD79b antibody-drug conjugate DCDS4501A in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Blood 2013, 122:4400.
19. Kuruvilla J, Byrd JC, Flynn J, et al. The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed/refractory non Hodgkin's lymphoma. Blood 2014, 124:396.
20. Herait P, Domret H, Thieblemont C, et al. BET-Bromodomain (BRD) inhibitor OTX015: final results of the dose-finding part of a phase I study in hematologic malignancies. Ann Oncol 2015, 26(suppl 2):ii10-ii11.
21. Friedberg JW, Mahadevan D, Jung J, et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B-and T-cell non-Hodgkin lymphoma (NHL). Blood 2011, 118:95.
22. Zaja F, Volpetti S, Chiappella A, et al. Panobinostat as salvage treatment for patients with relapsed/refractory diffuse large B-cell lymphoma not eligible to high dose therapy: a phase II study of the Fondazione Italiana Linfomi (FIL). Blood 2014, 124:1755.
23. Crump M, Andreadis C, Assouline SE, et al. A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas. J Clin Oncol 2013, 31:8535.
24. Younes A, Salles G, Bociek RG, et al. An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma. Blood 2014, 124:1718.
25. Persky DO, Bernstein SH, Goldman BH, et al. A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520. J Clin Oncol 2012, 30:e18536.
26. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008, 19:964-969.
27. Marks PA The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010, 19:1049-1066.
28. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
29. Elstrom RL, Martin P, Ostrow K, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk 2010, 10:192-196.
30. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013, 121:4021-4031.